Form 8-K NOVAVAX INC For: Jun 17
- Tech pulls Nasdaq, S&P 500 down as Treasury yields rise
- Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Oil up on tight supply, Brent crude nears $80 a barrel
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
(Exact name of registrant as specified in charter)
(State or Other Jurisdiction
|(Commission File Number)||
(Address of Principal Executive Offices, including Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Amended and Restated 2015 Stock Incentive Plan
As described in Item 5.07 below, at the Annual Meeting of Stockholders of Novavax, Inc. (the “Company”) held on June 17, 2021 (the “Annual Meeting”), the Company’s stockholders approved the proposal to amend and restate the Company’s Amended and Restated 2015 Stock Incentive Plan, as amended (as amended and restated, the “Amended 2015 Stock Plan”), to increase the number of shares of the Company’s common stock, par value $0.01 (“Common Stock”), available for issuance thereunder by 1,500,000 shares.
A description of the Amended 2015 Stock Plan was set forth in the Company’s Definitive Proxy Statement on Form 14A filed with the U.S. Securities and Exchange Commission on May 3, 2021 (the “2021 Proxy Statement”) and is incorporated herein by reference. The foregoing description of the Amended 2015 Stock Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended 2015 Stock Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting on June 17, 2021. Only stockholders of record as of April 20, 2021 (the “Record Date”) were entitled to vote at the Annual Meeting. As of the Record Date, there were 74,080,008 shares of Common Stock outstanding and entitled to vote at the Annual Meeting of which 54,435,897 shares were represented, in person virtually or by proxy, constituting a quorum on all matters voted upon. The final voting results of the Annual Meeting are as follows:
Proposal 1: Stockholders elected the following Class II nominees for director, each to serve a three-year term expiring at the 2024 Annual Meeting of Stockholders:
|Richard H. Douglas, Ph.D.||38,782,475||2,107,095||13,546,327|
|Margaret G. McGlynn, R. Ph.||39,310,707||1,578,863||13,546,327|
|David M. Mott||19,710,117||21,179,453||13,546,327|
Proposal 2: Stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers in 2020:
Proposal 3: Stockholders approved the Amended 2015 Stock Plan to increase the number of shares of Common Stock available for issuance thereunder by 1,500,000 shares:
|Proposal 4: Stockholders ratified certain April 2020 equity awards as described in the 2021 Proxy Statement:|
A majority of the total votes cast and a majority of the disinterested votes cast voted “for” Proposal 4.
|Proposal 5: Stockholders ratified certain June 2020 equity awards as described in the 2021 Proxy Statement:|
A majority of the total votes cast and a majority of the disinterested votes cast voted “for” Proposal 5.
Proposal 6: Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:
Item 9.01. Financial Statements and Exhibits.
|10.1||Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement filed on May 3, 2021 in connection with the Annual Meeting held on June 17, 2021 (File No. 000-26770)).|
|104||Cover Page Interactive Data File (formatted as Inline XBRL).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 24, 2021||By:||/s/ John A. Herrmann III|
|Name:||John A. Herrmann III|
|Title:||Executive Vice President, Chief Legal Officer and Corporate Secretary|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax's (NVAX) NanoFlu Influenza Vaccine Phase 3 Results Published in The Lancet ID; Vaccine Produced Significant Enhanced Humoral and Cellular Responses
- Freshworks Helps Dunzo Delight its Customers with Faster Support as it Scales Revenue
- Novavax (NVAX) and Serum Institute of India Apply to WHO for Emergency Use Listing of Novavax' COVID-19 Vaccine
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!